Syndex Bio

About Syndex Bio

Syndex Bio is a biotechnology firm that develops genomics-based tools for biological discovery. Founded in March 2022 by Geoff Smith, the company aims to accelerate the understanding, diagnosis, and treatment of diseases. The firm is headquartered in Cambridge, UK, with a presence in San Francisco, and has raised $15.5 million in a Series B funding round.

The company was established with the mission of integrating synthetic biology, molecular technologies, instrumentation, and artificial intelligence (AI) to create new tools for the life sciences, pharmaceutical, food, and agriculture industries. Its core offering is the Syndex AI Platform, which streamlines the analysis of biological samples, enabling more efficient data processing and deeper insights. This platform addresses challenges such as the inefficiency of traditional research methods and the complexity of analyzing biological data by providing tools like a Next-Generation Sequencing (NGS) workflow and a super-resolution imaging platform.

The founding team possesses significant experience in the genomics field. CEO and Co-founder Geoff Smith previously led the invention and development of the end-to-end NGS workflow at Illumina, which was instrumental in the development of the $1000 genome. Other key team members include Gary M. Skinner, who invented Illumina's super-resolution imaging platform, and experts in protein science and engineering.

Syndex Bio's business model is centered on providing its advanced platform to researchers to expedite drug discovery and diagnostics. The company operates in a competitive market that includes firms like DNAnexus, Cytel, and Metagenomi.